{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:17:39Z","timestamp":1793042259997,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To establish a high-performance liquid chromatography\u2013tandem mass spectrometry method (HPLC\u2013MS\/MS) to simultaneously determine colistin sulfate and tigecycline in human plasma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Polymyxin B<jats:sub>1<\/jats:sub> internal standard (20 \u00b5L) was added into 200 \u00b5L of plasma sample. The samples were treated with methanol-5% trichloroacetic acid (50:50, V\/V) solution, and the protein precipitation method was adopted for post-injection analysis. The chromatographic column was a Dikma C18 (4.6\u00a0mm \u00d7 150\u00a0mm, 5\u00a0\u03bcm). For the mobile phase, 0.1% formic acid in aqueous solution was used for phase A, 0.1% formic acid in acetonitrile solution for phase B, and gradient elution was also applied. The flow rate was 0.8 mL\/min, the column temperature was 40\u00a0\u00b0C, and the injection volume was 10 \u00b5L; Electrospray ionization and multiple reaction ion monitoring were adopted and scanned by the HPLC\u2013MS\/MS positive ion mode.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The endogenous impurities in the plasma had no interference in the determination of the analytes. There existed a good linear relationship of colistin sulfate within the range of 0.1\u201310\u00a0\u00b5g\/mL (R<jats:sup>2<\/jats:sup>\u2009=\u20090.9986), with the lower limit of quantification (LLOQ) of 0.1\u00a0\u00b5g\/mL. There existed a good linear relationship of tigecycline within the range of 0.05\u20135\u00a0\u00b5g\/ mL (R<jats:sup>2<\/jats:sup>\u2009=\u20090.9987), with the LLOQ of 0.05\u00a0\u00b5g\/mL. The intra- and inter-day relative standard deviations of colistin sulfate and tigecycline were both less than 15%, and the accuracy was between 88.21% and 108.24%. The extraction had good stability, the extraction recovery rate was 87.75\u201391.22%, and the matrix effect was 99.40\u2013105.26%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study successfully established a method for simultaneously detecting colistin sulfate and tigecycline plasma concentrations. The method was simple, rapid, and highly sensitive and could be applied for therapeutic medication monitoring.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13065-023-01109-8","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T12:02:09Z","timestamp":1705147329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Simultaneous determination of colistin sulfate and tigecycline in human plasma by liquid chromatography-tandem mass spectrometry method"],"prefix":"10.1186","volume":"18","author":[{"given":"Ying-Chao","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Kun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,13]]},"reference":[{"issue":"2","key":"1109_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1473-3099(16)30257-2","volume":"17","author":"H Grundmann","year":"2017","unstructured":"Grundmann H, Glasner C, Albiger B, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17(2):153\u201363.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"1109_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.00077-17","volume":"31","author":"R Domalaon","year":"2018","unstructured":"Domalaon R, Idowu T, Zhanel GG, et al. Antibiotic hybrids:the next generation of agents and adjuvants against gram-negative pathogens. Clin Microbiol Rev. 2018;31(2):1\u201345.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"1109_CR3","first-page":"205","volume":"862","author":"Z Ma","year":"2007","unstructured":"Ma Z, Wang JP, Gerber JP, et al. Determination of colistin in human plasma, urine and other biological samples using LC-MS\/MS. J Chromatogr B. 2007;862(1):205\u201312.","journal-title":"J Chromatogr B"},{"issue":"5","key":"1109_CR4","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.talanta.2010.11.044","volume":"83","author":"VD Bosschel","year":"2011","unstructured":"Bosschel VD, Schepdael AN, Chopra S, et al. Identification of impurities in polymyxin B and colistin bulk sample using liquid chromatography coupled to mass spectrometry. J Talanta. 2011;83(5):1521\u20139.","journal-title":"J Talanta"},{"issue":"4","key":"1109_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/09546630510011810","volume":"16","author":"N Scheinfeld","year":"2005","unstructured":"Scheinfeld N. Tigecycline:a review of a new glycylcycline antibiotic. J Dermatolog Treat. 2005;16(4):207\u201312.","journal-title":"J Dermatolog Treat"},{"issue":"8","key":"1109_CR6","doi-asserted-by":"publisher","first-page":"e9961","DOI":"10.1097\/MD.0000000000009961","volume":"97","author":"TT Geng","year":"2018","unstructured":"Geng TT, Xu X, Huang M. High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream Infections:a retrospective cohort study. J Med (Baltimore). 2018;97(8):e9961.","journal-title":"J Med (Baltimore)"},{"key":"1109_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/978-3-030-16373-0_17","volume":"1145","author":"JM Pogue","year":"2019","unstructured":"Pogue JM, Tam VH. Toxicity of in patients. J Adv Exp Med Biol. 2019;1145:289\u2013304.","journal-title":"J Adv Exp Med Biol"},{"key":"1109_CR8","doi-asserted-by":"crossref","unstructured":"Zavascki AP, Nation RL. Nephrotoxicity of polymyxins:is there any difference between colistimethate and polymyxin B? J Antimicrob Agents Chemother 2017,61(3):e02319\u201316.","DOI":"10.1128\/AAC.02319-16"},{"issue":"2","key":"1109_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/phar.1883","volume":"37","author":"T Liebenstein","year":"2017","unstructured":"Liebenstein T, Schulz T, Viesselmann C, et al. Effectiveness and safety of tigecycline compared with other broad-spectrum antimicrobials in abdominal solid organ transplant recipients with polymicrobial intraabdominal Infections. J Pharmacotherapy. 2017;37(2):151\u20138.","journal-title":"J Pharmacotherapy"},{"issue":"6","key":"1109_CR10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial theraputic drug monitoring in critically ill adult patients:a position paper. Intensive Care Med. 2020;46(6):1127\u201353.","journal-title":"Intensive Care Med"},{"issue":"4","key":"1109_CR11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.diagmicrobio.2014.04.007","volume":"79","author":"TW Felton","year":"2014","unstructured":"Felton TW, Hope WW, Roberts JA. How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it? Diagn Microbiol Infect Dis. 2014;79(4):441\u20137.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"1109_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jpba.2009.03.013","volume":"50","author":"I Clarot","year":"2009","unstructured":"Clarot I, Storme-Paris I, Chaminade P, et al. Simultaneous quantitation of tobramycin and colistin sulphate by HPLC with evaporative light scattering detection. J Pharm Biomed Anal. 2009;50(1):64\u20137.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"1109_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.4103\/wjtcm.wjtcm_73_20","volume":"7","author":"ZB Wang","year":"2021","unstructured":"Wang ZB, Ma Y, Liu H, et al. Simultaneous determination and pharmacokinetics of tetrandrine, fangchinoline, and cyclanoline in rat plasma by ultra-high performance liquid chromatography\u2013mass spectrometry after oral administration of stephaniae tetrandrae radix extract. World J Tradit Chin Med. 2021;7(1):130\u20137.","journal-title":"World J Tradit Chin Med"},{"key":"1109_CR14","doi-asserted-by":"publisher","first-page":"915958","DOI":"10.3389\/fphar.2022.915958","volume":"13","author":"XB Yu","year":"2022","unstructured":"Yu XB, Zhang XS, Wang YX, et al. Population Pharmacokinetics of Colistin Sulfate in critically Ill patients: exposure and clinical efficacy. Front Pharmacol. 2022;13:915958.","journal-title":"Front Pharmacol"},{"key":"1109_CR15","doi-asserted-by":"publisher","first-page":"113273","DOI":"10.1016\/j.jpba.2020.113273","volume":"186","author":"S Barco","year":"2020","unstructured":"Barco S, Mesini A, Barbagallo L, et al. A liquid chromatography-tandem mass spectrometry platform for the routine therapeutic drug monitoring of 14 antibiotics: application to critically ill pediatric patients. J Pharm Biomed. 2020;186:113273.","journal-title":"J Pharm Biomed"},{"key":"1109_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/978-3-030-16373-0_17","volume":"1145","author":"JM Pogue","year":"2019","unstructured":"Pogue JM, Tam VH. Toxicity of in patients. Adv Exp Med Biol. 2019;1145:289\u2013304.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"1109_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for anti-infective pharmacology (ISAP), society of critical Care Medicine (SCCM), and Society of Infectious Diseases pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10\u201339.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"1109_CR18","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1128\/AAC.01615-10","volume":"56","author":"MB Sujata","year":"2012","unstructured":"Sujata MB, Christopher MR, Jeffrey PH, et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired Pneumonia treated with tige- cycline. Antimicrob Agents Chemother. 2012;56(2):1065\u201372.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1109_CR19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/ijcp.12070","volume":"67","author":"V Avkanoguz","year":"2013","unstructured":"Avkanoguz V, Yapar N, Alpcavus S, et al. Clinical and microbiological efficacy of tigecycline for complicated skin-soft-tissue and intra-abdominal Infections in a Turkish university hospital. Int J Clin Pract. 2013;67(6):505\u201311.","journal-title":"Int J Clin Pract"},{"issue":"4","key":"1109_CR20","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1128\/AAC.01232-12","volume":"57","author":"J Ramirez","year":"2013","unstructured":"Ramirez J, Dartois N, Gandjini H, et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of Hospital-acquired Pneumonia. Antimicrob Agents Chemother. 2013;57(4):1756\u201362.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-023-01109-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-023-01109-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-023-01109-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T12:06:57Z","timestamp":1705147617000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcchem.biomedcentral.com\/articles\/10.1186\/s13065-023-01109-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,13]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1109"],"URL":"https:\/\/doi.org\/10.1186\/s13065-023-01109-8","relation":{},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,13]]},"assertion":[{"value":"5 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I confirm that I have read the Editorial Policy pages. This study was conducted with approval from the Ethics Committee of Second Hospital of Hebei Medical University, (2020-R551). This study was conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}